Sunday, May 31, 2015

Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial

… ) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial Opdivo … #8009). “Historically, treatment options for lung cancer patients have been limited. The … non-hematologic toxicities. About Non-Small Cell Lung Cancer Lung cancer is the leading cause of …

No comments:

Post a Comment